Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Dawn C. Buse et al.
Summary: The ongoing COVID-19 pandemic has had both negative and positive impacts on people living with migraine. Some individuals reported more frequent migraine attacks, while others reported fewer attacks. Negative impacts included interrupted medical care and increased stress, while greater access to healthcare was a positive impact.
Article
Clinical Neurology
Amy S. Grinberg et al.
Summary: The objective of this study was to evaluate the utilization of telehealth for headache services within the Veterans Health Administration's facilities and gather stakeholders' perspectives. The study found that during the pandemic, in-person visits decreased while video and telephone visits significantly increased. Patients and providers perceived value in using telehealth but faced technological barriers.
Review
Clinical Neurology
Pedro Augusto Sampaio Rocha-Filho
Summary: This review discusses the epidemiology, pathophysiology, characteristics, and management of COVID-19-associated headache. Headache is a common clinical symptom of COVID-19, affecting over half of the patients, especially young patients and those with a history of previous headaches. The headache usually occurs early in the symptomatic phase and has similar characteristics to tension-type headaches. The possible pathophysiological mechanisms include viral injury, inflammatory processes, and other mechanisms. Commonly used drugs for treatment include analgesics and nonsteroidal anti-inflammatory drugs.
Article
Clinical Neurology
Leon S. Moskatel et al.
Summary: This study retrospectively analyzed 31 patients who developed new or worsening persistent headaches after COVID-19 infection. The average duration of these headaches was 7.4 months, and most patients transitioned from episodic to chronic migraine. Additionally, there was a decrease in full-time employment, and the majority of patients who received preventive medication reported a decrease in headache frequency and/or severity.
Article
Clinical Neurology
Cesar Fernandez-de-las-Penas et al.
Summary: The study found that individuals infected with the Delta variant had a higher proportion of headache as a COVID-19 onset symptom at hospitalization, as well as a higher prevalence of headache 6 months after hospital discharge. Headache was a common symptom in subjects infected with the Wuhan, Alpha, and Delta variants but more prominent in those infected with the Delta variant.
Article
Clinical Neurology
Rehab Magdy et al.
Summary: This study aimed to assess the frequency and characteristics of headaches following different types of COVID-19 vaccines. The highest frequency of headaches was reported with adenoviral vector vaccines, followed by mRNA vaccines and then inactivated vaccines. Recipients of adenoviral vector vaccines experienced longer latency between vaccination and headache onset and higher headache intensity compared to recipients of inactivated vaccines. Female sex and thyroid disease were significantly associated with vaccine-related headaches.
Review
Clinical Neurology
Victor J. Gallardo et al.
Summary: This study aimed to investigate the relationship between headache and mortality in COVID-19 patients. The results showed that COVID-19 inpatients with headache had a significantly higher survival rate, suggesting a possible association between headache and COVID-19 survival.
Editorial Material
Clinical Neurology
Amy A. Gelfand et al.
Article
Clinical Neurology
Edoardo Caronna et al.
Summary: Studies show that post-COVID headache encompasses various types of headaches, requiring careful evaluation and further investigation into different underlying pathophysiological mechanisms.
Article
Clinical Neurology
Chia-Chun Chiang et al.
Summary: The study evaluated the patient experience of telemedicine for headache care during the COVID-19 pandemic, finding that many patients were highly satisfied with telemedicine and expressed a desire to continue using it for future headache care.
